Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to equity ratio is N/A as of Tuesday, October 6, 2026.
DEBT TO EQUITY RATIO
N/A
Market Cap
$866.05M
Debt to Equity Ratio
0.03
TTM Avg
0.07
3Y Avg
0.07
5Y Avg
0.07
Market Cap
$853.35M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$851.97M
Debt to Equity Ratio
0.08
TTM Avg
0.18
3Y Avg
0.20
5Y Avg
0.16
Market Cap
$892.20M
Debt to Equity Ratio
0.00
TTM Avg
0.03
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$896.17M
Debt to Equity Ratio
0.01
TTM Avg
0.06
3Y Avg
0.07
5Y Avg
0.10
Market Cap
$821.12M
Debt to Equity Ratio
0.03
TTM Avg
0.02
3Y Avg
0.02
5Y Avg
0.03
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $851.42M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $866.05M | 0.03 | 0.07 | 0.07 | 0.07 |
| Jade Biosciences, Inc. (JBIO)vs › | $853.35M | 0.00 | 0.01 | 0.01 | 0.01 |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $851.97M | 0.08 | 0.18 | 0.20 | 0.16 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $892.20M | 0.00 | 0.03 | 0.03 | 0.03 |
| Arbutus Biopharma Corp (ABUS)vs › | $896.17M | 0.01 | 0.06 | 0.07 | 0.10 |
| Alumis Inc. (ALMS)vs › | $830.08M | 0.08 | 0.12 | 0.12 | 0.12 |
| Ardelyx, Inc. (ARDX)vs › | $823.84M | 1.72 | 1.08 | 0.72 | 0.64 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $821.12M | 0.03 | 0.02 | 0.02 | 0.03 |
| InMode Ltd. (INMD)vs › | $814.22M | 0.01 | 0.01 | 0.01 | 0.01 |
Debt/Equity
N/A
Current Ratio
N/A
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
